Alto Neuroscience
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Alto Neuroscience sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
Alto Neuroscience: 10 sponsored US clinical trials, 4 recruiting.
Alto Neuroscience sponsors 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Major Depressive Disorder, with 5 trials.
Top-decile sponsor footprint
Alto Neuroscience ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
10 total, page 1 of 1
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637
ALTO-100 in Bipolar Disorder With Depression (BD-D)
NCT06656416
Study of ALTO-101 in Patients With Schizophrenia
NCT06502964
Study of ALTO-300 in MDD
NCT05922878
PD, PK, and Safety of ALTO-203 in Patients With MDD
NCT06391593
Phase 2b Study of ALTO-100 in MDD
NCT05712187
Pilot Decentralized Trial
NCT05419869
ALTO-300 in Depression (ALTO-300-004)
NCT05157945
ALTO-100 in MDD and/or PTSD
NCT05117632
ALTO-300 in Depression
NCT05118750
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 10 |
What is open in the Alto Neuroscience pipeline
4 recruiting of 10 indexed (40% open); 6 completed (60%).
Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Major Depressive Disorder (5 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alto Neuroscience: open-pipeline peers nationwide
Peers matched on 10 registered trials and 40% open enrollment, not the therapeutic-area sidebar.
Alto Neuroscience sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 trials (± recruiting share)
- Adamas Pharmaceuticals · 10 trials · 0% recruiting
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Aevi Genomic Medicine, LLC, a Cerecor company · 10 trials · 0% recruiting
- Agouron Pharmaceuticals · 10 trials · 0% recruiting
Sponsors near 40% open enrollment (± trial volume)
- Ad scientiam · 40% recruiting · 5 trials
- Bonafide Health · 40% recruiting · 5 trials
- Brooks Rehabilitation · 40% recruiting · 5 trials
- C4 Therapeutics · 40% recruiting · 5 trials
Related
What to do with this Alto Neuroscience page
10 registered trials is a research-attention snapshot, not an endorsement of Alto Neuroscience or any single study.
- 4 of Alto Neuroscience's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Major Depressive Disorder is the condition Alto Neuroscience studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Major Depressive Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Alto Neuroscience pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.